Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 730-735

  Cano, Florencia ^a,c   Pannel, Richard ^a,c   Follows, George A ^a,b,c   Rabbitts, Terence H ^a,c,d  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYTARABINE;

ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL POPULATION; CHROMOSOME TRANSLOCATION; DRUG SENSITIVITY; ENL GENE; EXPERIMENTAL MODEL; GENE; LEUKEMIA; LYMPHOID CELL; MII GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTARABINE; LEUKEMIA, EXPERIMENTAL; MICE; MODELS, THEORETICAL; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION;

EID: 41649107054     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2032     Document Type: Article

References (12)

1. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54.
2. Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 2005;11:971-81.
3. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene Rev 2001;20:5695-707.
4. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997;278:1059-65.
5. Pui C-H, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Eng J Med 1989;321:136-42.
6. Huret JL, Dessen P, Bernheim A. An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL. Leukaemia 2001;15:987-99. 7. Forster A, Pannell R, Drynan LF, et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 2003;3:449-58.
7. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002;100:238-45.
8. Burnett AK. The treatment of AML : current status and novel approaches. Haematology 2005;10:50-3.
9. Collins EC, Pannell R, Simpson EM, Forster A, Rabbitts TH. Interchromosomal recombination of Mll and Af9 genes mediated by Cre-loxP in mouse development. EMBO Rep 2000;1:127-32.
10. McCormack MP, Forster A, Drynan LF, Pannell R, Rabbitts TH. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol Cell Biol 2003;3:9003-13.
11. Crisp LB, Smith SM, Mathers MA, Young GA, Lyons SD, Christopherson RI. Effects of cytosine arabinoside on human leukemia cells. Int J Biochem Cell Biol 1996;28:1061-9.
12. de Vries JF, Falkenburg JH, Willemze R, Barge RM. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 2006;91:912-9.